Investigative Ophthalmology & Visual Science, Vol 34, 3232-3245, Copyright © 1993 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Nerve growth factor promotes functional recovery of retinal ganglion cells after ischemia

R Siliprandi, R Canella and G Carmignoto
Fidia Research Laboratories, Abano Terme, Italy.

PURPOSE. To investigate the effect of a transient complete ischemia on the function of cat retina and to determine whether nerve growth factor (NGF), which was previously shown to enhance retinal ganglion cell (RGC) survival after optic nerve section in the adult rat, can promote recovery of retinal neurons after the ischemic insult. METHODS. Function of distal and proximal retina was assessed by recording the electroretinogram in response to both homogeneous flickering light (FERG) and contrast reversing gratings (PERG), respectively, 30 days after the induction of a 60-minute episode of ischemia. Visual evoked potentials in response to contrast reversing gratings were also recorded to evaluate visual acuity and contrast thresholds. Cell survival after ischemia was assessed in retinal whole-mounts stained with cresyl violet. Cats were intraocularly treated with NGF every other day, 3 times a week, for 30 days. Controls were treated with either phosphate buffered saline or cytochrome c. RESULTS. After ischemia, the FERG was not significantly affected. On the contrary, the PERG, visual acuity, and contrast thresholds were severely impaired. After NGF treatment, PERG response amplitudes were much less reduced compared to controls, and visual acuity and contrast thresholds were virtually normal. In addition, a larger number of presumed RGCs was present in the NGF-treated retinas compared to the cyt c-treated ones. CONCLUSIONS. The more proximally located retinal neurons, in particular RGCs, are highly vulnerable to ischemia. Intraocular NGF treatment was effective in enhancing the survival and functional recovery of these neurons. This suggests that NGF may represent a novel therapeutic agent for the treatment of ischemic ocular pathologies.

This article has been cited by other articles:

				A. J. Weber, C. D. Harman, and S. Viswanathan Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina J. Physiol., September 15, 2008; 586(18): 4393 - 4400. [Abstract] [Full Text] [PDF]

				H. Kergoat, M.-E. Herard, and M. Lemay RGC Sensitivity to Mild Systemic Hypoxia Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5423 - 5427. [Abstract] [Full Text] [PDF]

				A. Lambiase, P. Tirassa, A. Micera, L. Aloe, and S. Bonini Pharmacokinetics of Conjunctivally Applied Nerve Growth Factor in the Retina and Optic Nerve of Adult Rats Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3800 - 3806. [Abstract] [Full Text] [PDF]

				M. Garcia, V. Forster, D. Hicks, and E. Vecino In Vivo Expression of Neurotrophins and Neurotrophin Receptors Is Conserved in Adult Porcine Retina In Vitro Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4532 - 4541. [Abstract] [Full Text] [PDF]

				A. Lambiase, S. Bonini, L. Manni, E. Ghinelli, P. Tirassa, P. Rama, and L. Aloe Intraocular Production and Release of Nerve Growth Factor after Iridectomy Invest. Ophthalmol. Vis. Sci., July 1, 2002; 43(7): 2334 - 2340. [Abstract] [Full Text] [PDF]

				H. Shibuki, N. Katai, S. Kuroiwa, T. Kurokawa, J. Arai, K. Matsumoto, T. Nakamura, and N. Yoshimura Expression and Neuroprotective Effect of Hepatocyte Growth Factor in Retinal Ischemia-Reperfusion Injury Invest. Ophthalmol. Vis. Sci., February 1, 2002; 43(2): 528 - 536. [Abstract] [Full Text] [PDF]

				M. P. Lafuente, M. P. Villegas-Perez, P. Sobrado-Calvo, A. Garcia-Aviles, J. Miralles de Imperial, and M. Vidal-Sanz Neuroprotective Effects of {alpha}2-Selective Adrenergic Agonists against Ischemia-Induced Retinal Ganglion Cell Death Invest. Ophthalmol. Vis. Sci., August 1, 2001; 42(9): 2074 - 2084. [Abstract] [Full Text] [PDF]

				S. De Santis, A. Pace, L. Bove, F. Cognetti, F. Properzi, M. Fiore, V. Triaca, A. Savarese, M. D. Simone, B. Jandolo, et al. Patients Treated with Antitumor Drugs Displaying Neurological Deficits Are Characterized by a Low Circulating Level of Nerve Growth Factor Clin. Cancer Res., January 1, 2000; 6(1): 90 - 95. [Abstract] [Full Text]

				A. Micera, A. Lambiase, P. Rama, and L. Aloe Altered nerve growth factor level in the optic nerve of patients affected by multiple sclerosis Multiple Sclerosis, December 1, 1999; 5(6): 389 - 394. [Abstract] [PDF]

				T. Abe, D. A. Morgan, and D. D. Gutterman Protective Role of Nerve Growth Factor Against Postischemic Dysfunction of Sympathetic Coronary Innervation Circulation, January 7, 1997; 95(1): 213 - 220. [Abstract] [Full Text]